INTRODUCTION
============

Taurine, 2-aminoethane sulfonic acid, is classified as a β-amino acid. It has unique structural features such as the presence of sulfonic group and its β-form configuration ([@b49-bt-27-450]).

Though taurine is present in the body, its supply from diet is necessary due to the relatively low activity of the enzyme cysteinsulfinic acid decarboxylase that is the major regulator of taurine biosynthesis. Taurine is biosynthesized from cysteine and methionine mostly in the liver and synthesized taurine is transported to other organs through the taurine transporter ([@b17-bt-27-450]; [@b16-bt-27-450]).

Strikingly, taurine is present in the brain in a large amount and it exerts many important neuronal functions such as anticonvulsant, regulation of neuronal excitability, learning and memory formation, anti-aggressiveness, enhancing CNS development and anti-alcoholic effect ([@b18-bt-27-450]).

There is an interesting proposal that taurine and its derivative glutaurine could work as a neurotransmitter or neuromodulator. Furthermore, taurine plays important roles in regulating the structural stability of cell membrane as well as depolarization-associated calcium channel activity ([@b23-bt-27-450]; [@b26-bt-27-450]; [@b35-bt-27-450]; [@b44-bt-27-450]).

The physiological importance of taurine was further supported by the study with taurine deficiency: generation of epilepsy is associated with taurine deficiency ([@b4-bt-27-450]).

Taurine has been found to have potential anxiolytic effects in animal models ([@b5-bt-27-450]; [@b21-bt-27-450]) and zebrafish models ([@b42-bt-27-450]; [@b12-bt-27-450], [@b13-bt-27-450]; [@b33-bt-27-450]); however, its exact mechanism of action remains to be fully characterized.

Benzodiazepines have long been used for the treatment of anxiety; however, various unwanted side effects have been reported such as memory impairment, addiction problem, and muscle relaxation. Thus, it will be necessary to develop new drugs with fewer side effects for the safety of patients. Considering that taurine is an agonist of strychnine-sensitive glycine receptors present in the rat striatum ([@b43-bt-27-450]), there is a good possibility that taurine could interact with the glycine receptor *in vivo*. However, the use of taurine for the brain is extremely difficult due to its poor penetration rate into the brain: taurine has a strong hydrophilicity and has sulfonic acid instead of carboxylic acid which makes it very hard to penetrate the blood brain barrier ([@b6-bt-27-450]). Recently, intranasal administration methods have been used as an alternative route for the efficient delivery of bioactive molecules into the brain. Numerous studies have been reported dealing with the delivery of neuropeptides and proteins to the brain via nasal route ([@b19-bt-27-450]). Intranasal delivery of peptides has been employed for the treatment of neurodegenerative diseases ([@b32-bt-27-450]). It could allow for taurine to bypass the blood brain barrier, and thereby taurine could enter CNS via other routes such as trigeminal nerve and intercellular cleft in the olfactory epithelium ([@b22-bt-27-450]; [@b27-bt-27-450]).

In the present study, the possibility of nasal delivery of taurine to the CNS has been tested. We have presented evidence that taurine could be delivered to the brain, causing anti-anxiety action.

MATERIALS AND METHODS
=====================

Animals
-------

Male ICR mice were purchased from Hanlim Experimental Animals Co (Hwaseong, Korea). Male ICR (25--30 g, 6 weeks old) mice were caged in a temperature (22 ± 2°C) and ventilation-controlled room with a 12-h light/dark cycle. A standard pellet diet and tap water were supplied *ad libitum*. Throughout the experiments, animals were processed according to the Animal Care and Use Guidelines issued by Kyung Hee University (Seoul, Korea). All experiment protocols were approved by the Institutional Animal Care and Use Committee of Kyung Hee University \[KHUASP(SE)-15-114\]. After one week of acclimation period, animals were used for the experiment. Strychnine, picrotoxin, yohimbine and isoniazid were purchased from Tocris (Minneapolis, MN, USA).

Intranasal taurine delivery to mice
-----------------------------------

Intranasal (IN) delivery of taurine was carried out as essentially described by [@b37-bt-27-450]. Briefly, mice were hand-restrained, placed in a supine position, and given five 10 microliter drops of 80 μg/μl taurine or saline (0.9%), into both nares to give 200 mg of taurine per kg body weight through a micropipette (Pipetman P-20, Gilson, Inc., Middleton, WI, USA). Mice were given an extra ten microliter treatment drop if the subject forcibly ejected or sneezed out solution. Mice were held supine for 5--10 s after delivery to make sure all taurine containing solution was inhaled.

Elevated plus maze test
-----------------------

The plus maze, consisting of two open arms (60×5 cm) and two enclosed arms (60×5×20 cm) and elevated to a height of 60 cm, was used as described earlier by [@b40-bt-27-450]. Mice were treated with saline or taurine (200 mg/kg, IN) and 60 min later were placed individually in the center of the plus maze, facing the enclosed arm. The time spent in the enclosed and open arms and the number of entries to the enclosed and open arms during the 5-min test period were recorded.

Activity Cage test
------------------

Groups of 10 mice with a weight between 35 and 40 g were used. They were treated intranasally with saline or taurine (200 mg/kg, IN). 1 h later, the mice were tested for spontaneous locomotor activity associated with anxiety for 4 min by the use of Activity Cage purchased from Ugo Basile (Gemonio, Italy) ([@b1-bt-27-450]; [@b47-bt-27-450]). Briefly, following the treatment of taurine or saline, the mice were evaluated for horizontal and vertical activities for 4 min according to the provider's instruction manual.

Rota rod test
-------------

Each mouse was trained to run in a Rota rod (3 cm in diameter, 15 rpm) until it could remain there for 300 s without falling. The mice were then evaluated in a Rota rod performance test for 300 s, 60 min after distilled water or taurine (200 mg/kg, IN) treatment ([@b45-bt-27-450]).

Passive avoidance test
----------------------

The test was basically performed according to the step-through method described earlier ([@b39-bt-27-450]). The Gemini Avoidance System (SD Instruments, San Diego, CA, USA) was used for this experiment. The apparatus consisted of a two-compartment acrylic box with a lightened compartment connected to a darkened one by an automatic guillotine door. Mice were placed in the lighted box for 300 s, then the guillotine door was opened. The mice, as soon as they entered the dark compartment, received a punishing electrical shock (0.3 mA, 1 s). The latency times for entering the dark compartment were measured in the training test and after 24 h in the retention test. The maximum entry latency allowed in the retention session was 180s ([@b34-bt-27-450]). Taurine (200 mg/kg, IN) or distilled water were administered 60 min prior to the training session of passive avoidance test.

Strychnine-Induced convulsions
------------------------------

Groups of 10 mice with a weight between 35 and 40 g were used. They were treated intranasal with distilled water or taurine (200 mg/kg, IN). 1 h later the mice were injected with 2 mg/kg strychnine i.p. The time until occurrence of tonic extensor convulsion and death was noted during a 1-h period ([@b3-bt-27-450]).

Picrotoxin-Induced convulsions
------------------------------

Groups of 10 mice with a weight between 35 and 40 g were used. They were treated intranasal with distilled water or taurine (200 mg/kg, IN). 1 h later the mice were injected with 3.5 mg/kg picrotoxin s.c. The time until occurrence of clonic seizure was noted during a 30-min period ([@b46-bt-27-450]).

Yohimbine-Induced convulsions
-----------------------------

Groups of 10 mice with a weight between 35 and 40 g were used. They were treated intranasal with distilled water or taurine (200 mg/kg, IN). 1 h later the mice were injected with 45 mg/kg yohimbine s.c. The time until occurrence of clonic seizure during a 60-min period was recorded ([@b9-bt-27-450]).

Isoniazid-Induced convulsions
-----------------------------

Groups of 10 mice with a weight between 35 and 40 g were used. They were treated intranasal with distilled water or taurine (200 mg/kg, IN). 1 h later the mice were injected with 45 mg/kg isoniazid s.c. The time until occurrence of clonic and tonic seizures and the time to death were recorded during a 2-h period ([@b32-bt-27-450]).

Statistical analysis
--------------------

Each value is expressed as the mean and standard error of the mean (SEM) of multiple determinations. All statistical analyses were used Prism 5.0 software (GraphPad Software, San Diego, CA, USA). Analysis of a non-parametric unpaired *t*-test were used. The differences were considered statistically significant at *p*\<0.05.

RESULTS
=======

Elevated plus maze test
-----------------------

Elevated plus maze test was employed to explore the potential anti-anxiety actions of intra nasally (IN) administered taurine. There was no significant difference in terms of total arms entries ([Fig. 1A](#f1-bt-27-450){ref-type="fig"}) and total time spent in the arms ([Fig. 1B](#f1-bt-27-450){ref-type="fig"}) between control and taurine groups.

Administration of taurine (200 mg/kg, IN) caused a significant increase in the percent open arm entries (open arm/total×100): control and taurine (200 mg/kg) were 28.7% and 45.7%, respectively ([Fig. 1C](#f1-bt-27-450){ref-type="fig"}). Percent time spent in open arms was also significantly increased by taurine treatment (200 mg/kg, IN): control and taurine (200 mg/kg) were 12.6% and 33.6%, respectively ([Fig. 1D](#f1-bt-27-450){ref-type="fig"}). The actual time spent in open arms in control group and taurine treated group was 0.49 min and 1.16 min, respectively ([Fig. 1E](#f1-bt-27-450){ref-type="fig"}). The actual number of entries in open arms in control group and taurine treated group was 3.43 min and 2.27 min, respectively ([Fig. 1F](#f1-bt-27-450){ref-type="fig"}).

Activity cage test
------------------

Activity cage tests are another widely accepted as an experimental tool to test anti-anxiety actions of drugs. Following taurine administration (200 mg/kg, IN), mice were delivered to the activity cage for 4 min, and evaluated for horizontal and vertical activities. Taurine treatment caused a decrease in the horizontal steps by 43%, and it also diminished the vertical steps by 81% as compared to controls ([Fig. 2](#f2-bt-27-450){ref-type="fig"}).

Rota rod test
-------------

To explore the potential effect of taurine on the muscle relaxation, rota rod test were performed. Taurine administration (200 mg/kg, IN) did not cause any significant changes on the rota rod test, suggesting it had little effect on muscle relaxation ([Fig. 3](#f3-bt-27-450){ref-type="fig"}).

Passive avoidance test
----------------------

To evaluate taurine's potential effect on the memory formation, passive avoidance test was carried out. Taurine administration via intra nasal route (200 mg/kg, IN) did not change the retention times in the training and test session, suggesting it has little direct effect on the memory function ([Fig. 4](#f4-bt-27-450){ref-type="fig"}).

Convulsions test
----------------

Taurine, at a dose 200 mg/kg, increased the latency to the onset of the first clonic seizure caused by strychnine by 40% as compared to control ([Fig. 5](#f5-bt-27-450){ref-type="fig"}). Taurine prolonged the induction time of death by 20% as compared to control, ([Fig. 5](#f5-bt-27-450){ref-type="fig"}). However, taurine had little effect on the latency to the onset of convulsion caused by picrotoxin ([Fig. 6](#f6-bt-27-450){ref-type="fig"}) and yohimbine ([Fig. 7](#f7-bt-27-450){ref-type="fig"}). Taurine had little effect on the latency to the clonic and tonic seizures as well as the time of death caused by isoniazid ([Fig. 8](#f8-bt-27-450){ref-type="fig"}).

DISCUSSION
==========

Taurine, as a derivative of cysteine, exerts a wide variety of pharmacological actions in the body including CNS effects such as neuroprotection and anti-anxiety. Taurine have been extensively studied by many investigators in peripheral tissues; however, its actions in the CNS were not fully understood. As an alternative route of taurine administration, the possibility of nasal delivery of taurine to the brain was tested. We present evidence that taurine is readily transported into the brain via intranasal delivery, causing anxiolytic effects.

Taurine, 2-aminoethane sulfonic acid, is an important amino acid derivative playing essential physiological roles in the body such as bile acid conjugation, osmoregulation, cardiovascular regulation, antioxidation etc. Interestingly, taurine can be transported to the brain and can induce a number of CNS actions including anti-anxiety effect. However, its poor transport to the brain has limited its clinical application. We have previously found that taurine administration via PER ORAL could induce significant anti-anxiety effect through the activation of strychnine-sensitive glycine receptor ([@b49-bt-27-450]): this prompted us to further investigate the possibility of intranasal delivery of taurine for its anti-anxiety action. The anxiolytic action of taurine via intranasal delivery was evidenced by the activity cage test as well as the elevated plus maze test. It has been suggested that a decrease of horizontal and vertical activity by an agent is well correlated with its anxiolytic action ([@b2-bt-27-450]).

Spontaneous locomotor activity measured by the activity cage test is regarded as an index of the level of excitability of the CNS ([@b36-bt-27-450]). Drug that causes a decrease of spontaneous locomotor activity can be anxiolytic ([@b38-bt-27-450]). In the activity cage test, taurine administration via intranasal route caused remarkable reduction of horizontal and vertical activities, suggesting taurine's anti-anxiety action. The activation of strychnine-sensitive glycine receptor by taurine could cause hyperpolarization of neuronal membrane via the receptor-associated chloride channels, which might lead to the anxiolytic action.

Elevated plus maze test is a commonly accepted tool for the evaluation of anti-anxiety action ([@b40-bt-27-450]). It is well documented that anxiolytic molecules increase the time spent in open arm in the elevated plus maze test. Taurine's anti-anxiety action via intranasal delivery was clearly evident in the elevated plus maze test: the time spent in the open arm was significantly increased. Taurine administration via intranasal delivery has little effect on the muscle relaxation as shown by the Rota rod test. This feature of taurine is beneficial as compared to the conventional anxiolytic drug such as benzodiazepine which has muscle relaxation activity.

To explore the mechanism of taurine's anti-anxiety action caused by intranasal delivery, convulsions induced by strychnine, picrotoxin, yohimbine or isoniazid were tested. The doses of strychnine, picrotoxin, yohimbine and isoniazid employed in the convulsion tests are widely used for the study of anxiolytic effects of compounds ([@b7-bt-27-450], [@b8-bt-27-450]; [@b9-bt-27-450]).

GABA~A~ receptor is a ligand-gated chloride channel which has multiple binding sites for picrotoxin, yohimbine as well as GABA ([@b25-bt-27-450]).

Anion-selective transmitter-gated ion channels of the cysloop super family contain GABA~A~ receptors and strychnine-sensitive glycine receptors ([@b48-bt-27-450]). The binding of GABA to GABA~A~ receptor causes a conformational change of the receptor complex, resulting in the hyperpolarization of neuronal cells via opening the chloride channel. By contrast, binding of picrotoxin or yohimbine to the GABA~A~ receptor complex blocks the opening of chloride channel, causing convulsion. Thus, the present results that intranasal administration of taurine had little effect on the picrotoxin- and yohimbine-induced convulsion clearly suggest that taurine's anti-anxiety action is not mediated by GABA~A~ receptor. Since there is a possibility that taurine may affect the synthesis of GABA, isoniazid was employed. Isoniazid is a drug for the treatment of tuberculosis, but it also has been known to inhibit GABA synthesis and thereby inducing convulsion ([@b8-bt-27-450]).

When taurine was administered via intranasal route with the pretreatment of isoniazid, the convulsions induced by isoniazid were not affected. These results indicate that taurine has little effect on GABA synthesis process. Glycine receptor is another ligand-gated chloride channel which has a different structure as compared to the GABA~A~ receptor. Activation of glycine receptor by binding with glycine induces a conformational change on the receptor and subsequently opens the associated chloride channel, causing sedation ([@b14-bt-27-450]).

Strychnine-sensitive glycine receptors are pentameric anion channel consisting of α1-α4 and β ([@b28-bt-27-450]) and have a specific binding site for strychnine. When strychnine binds to the glycine receptor, it is inactivated with the associated chloride channel being closed, and eventually leading to convulsion. The strychnine-sensitive glycine receptors are expressed in various brain regions such as hippocampus, brain stem, spinal cord, cerebellum and retina ([@b24-bt-27-450]; [@b48-bt-27-450]). They are playing important role in regulating respiratory rhythm, muscle tone, pain/sensory transmission and convulsion ([@b15-bt-27-450]; [@b41-bt-27-450]; [@b10-bt-27-450]; [@b29-bt-27-450]). A recent report has suggested a potential role of the strychnine-sensitive glycine receptor ([@b20-bt-27-450]) in the control of anxiety. In the present study, the intranasal taurine delivery increased the time to induce convulsion caused by strychnine, suggesting taurine may exert anti-anxiety action through the activation of strychnine-sensitive glycine receptors.

Recently, the intranasal delivery of peptide and protein draws much attention as it provides an alternative route of CNS drug delivery ([@b32-bt-27-450]). Intranasal peptides and proteins directly diffuse into the brain through the intercellular cleft in the olfactory epithelium as well as through the trigeminal nerve ([@b22-bt-27-450]; [@b27-bt-27-450]). Interestingly, it has been found that there is indirect pathway for molecules to be transported in the brain via lymphatic or vasculature system and subsequently through blood brain barrier. We propose that the intranasally administered taurine could be transported to the brain via direct pathway(s) containing olfactory epithelium and/or trigeminal nerve. However, we cannot rule out the possibility that intra-nasally administered taurine may enter the brain lymphatic or vasculature system and subsequently pass through the blood brain barrier, exerting its anti-anxiety action. Since strychnine-sensitive glycine receptors are expressed hippocampus, brain stem, spinal cord, cerebellum and retina ([@b24-bt-27-450]; [@b48-bt-27-450]), taurine transported via the intranasal pathway may interact with the strychnine-sensitive glycine receptors in the aforementioned brain regions and thereby inducing its CNS actions including anxiolytic activity. It has been found that the strychnine-sensitive glycine receptors are also expressed in adult rat amygdala ([@b30-bt-27-450]) and taurine can activate these receptors ([@b31-bt-27-450]); this finding suggests that the intranasally delivered taurine could interact with the strychnine-sensitive glycine receptor to regulate anxiety in amygdala which plays important role in the regulation of emotion. It is also possible that taurine-induced anxiolytic behavior is mediated by dopamine regulation, considering that taurine elevates dopamine levels in nucleus accumbens ([@b11-bt-27-450]).

Taken together, it has been clearly demonstrated that taurine could be delivered to the brain system via intranasal route, inducing anti-anxiety action. These results suggest that intranasal administration could be an alternative route for the delivery of taurine into the brain to induce anti-anxiety action. Intranasal delivery of taurine could be considered in clinical situations requiring anxiety control. In conclusion, taurine exerts a significant anti-anxiety action via intranasal delivery, possibly due to its binding to and activating strychnine-sensitive glycine receptor *in vivo*. Future studies are necessary to compare the efficacy of intranasal administration of taurine with other administration routes.

![Effect of taurine on anxiety in the elevated plus maze test in mice. Following taurine administration (200 mg/kg, IN), the elevated plus maze test was performed as described in the Materials and Methods. Data are expressed as mean ± SEM. ^\*^*p*\<0.05; ^\*\*^*p*\<0.01; ^\*\*\*^*p*\<0.001, compared to the control group (n=8).](bt-27-450f1){#f1-bt-27-450}

![Effect of taurine on spontaneous locomotor activity in the activity cage test in mice. Following taurine administration (200 mg/kg, IN) the activity cage test was performed as described in the Materials and Methods. Data are expressed as mean ± SEM. ^\*\*^*p*\<0.01; ^\*\*\*^*p*\<0.001, compared to the control group (n=8).](bt-27-450f2){#f2-bt-27-450}

![Effect of taurine on muscle relaxation in the Rota rod test in mice. Following taurine administration (200 mg/kg, IN), the Rota rod test was carried out as described in the Materials and Methods. The time spent on the Rota rod was measured. Data are expressed as mean ± SEM (n=8).](bt-27-450f3){#f3-bt-27-450}

![Effect of taurine on cognition in the passive avoidance test in mice. Following taurine administration (200 mg/kg, IN), passive avoidance test was performed as described in the Materials and Methods. Latency to enter the dark compartment was measured in the training test and the retention. Data are expressed as mean ± SEM (n=8).](bt-27-450f4){#f4-bt-27-450}

![Effect of taurine on the strychnine-induced convulsion in mice. Following taurine administration (200 mg/kg, IN), convulsion was induced by strychnine as described in the Materials and Methods. Latency to convulsion and the time of death was measured. Data are expressed as mean ± SEM. ^\*\*^*p*\<0.01, compared to the control group (n=8).](bt-27-450f5){#f5-bt-27-450}

![Effect of taurine on the picrotoxin-induced convulsion in mice. Following taurine administration (200 mg/kg, IN), convulsion was induced by picrotoxin as described in the Materials and Methods. Latency to convulsion was measured. Data are expressed as mean ± SEM (n=8).](bt-27-450f6){#f6-bt-27-450}

![Effect of taurine on the yohimbine-induced convulsion in mice. Following taurine administration (200 mg/kg, /IN), convulsion was induced by yohimbine as described in the Materials and Methods. Latency to convulsion was measured. Data are expressed as mean ± SEM (n=8).](bt-27-450f7){#f7-bt-27-450}

![Effect of taurine on the isoniazid-induced convulsion in mice. Following taurine administration (200 mg/kg, IN), convulsion was induced by isoniazid as described in the Materials and Methods. Latency to (A) clonic and (B) tonic seizures and (C) the time of death was measured. Data are expressed as mean ± SEM (n=8).](bt-27-450f8){#f8-bt-27-450}
